{"id":499440,"date":"2020-07-29T13:04:02","date_gmt":"2020-07-29T13:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499440"},"modified":"2020-07-29T13:04:02","modified_gmt":"2020-07-29T13:04:02","slug":"autosomal-dominant-polycystic-kidney-disease-adpkd-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autosomal-dominant-polycystic-kidney-disease-adpkd-pipeline-assessment-key-companies-and-emerging-drugs_499440.html","title":{"rendered":"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Assessment, Key Companies And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Assessment, Key Companies And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight report provides in-depth analysis of&nbsp;<strong>Autosomal Dominant Polycystic Kidney Disease (ADPKD) commercial assessment and clinical assessment<\/strong> along with pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal Dominant Polycystic Kidney Disease (ADPKD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get FREE sample copy at:&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/autosomal-dominant-polycystic-kidney-disease-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/autosomal-dominant-polycystic-kidney-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"autosomal-dominant-polycystic-kidney-disease-pipeline-insight\" src=\"https:\/\/www.abnewswire.com\/uploads\/ba7737a48543c91337f38eb20d77d585.jpg\" alt=\"autosomal-dominant-polycystic-kidney-disease-pipeline-insight\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key Pharma companies are involved in the development of therapies for the treatment of ADPKD patients. Owing to the launch of these emerging therapies, the market scenario of ADPKD may significantly impacted in the coming years 2020&ndash;2030..<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Key players in the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market includes:<\/strong><br \/>Kyowa Hakko Kirin<br \/>Palladio Biosciences<br \/>Sanofi<br \/>Reata Pharmaceuticals<br \/>Regulus Therapeutics<br \/>And may others<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs covered<\/strong><br \/>Venglustat<br \/>Bardoxolone<br \/>Lixivaptan<br \/>RGLS4326<br \/>XRx-008<br \/>And others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autosomal-dominant-polycystic-kidney-disease-pipeline-insight\" target=\"_blank\"><strong>The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Analysis&nbsp;<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Autosomal Dominant Polycystic Kidney Disease (ADPKD) key players<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Autosomal Dominant Polycystic Kidney Disease (ADPKD) market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <strong>Autosomal Dominant Polycystic Kidney Disease (ADPKD) Report<\/strong> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease (ADPKD) across the complete product development cycle, including all clinical and nonclinical stages.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It comprises of detailed profiles of Autosomal Dominant Polycystic Kidney Disease (ADPKD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed Autosomal Dominant Polycystic Kidney Disease (ADPKD) research and development progress and trial details, results wherever available, are also included in the pipeline study.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Autosomal Dominant Polycystic Kidney Disease (ADPKD).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD).&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">In the coming years, the <strong>Autosomal Dominant Polycystic Kidney Disease (ADPKD) market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The companies and academics that are working to assess challenges and seek opportunities that could influence Autosomal Dominant Polycystic Kidney Disease (ADPKD) R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autosomal-dominant-polycystic-kidney-disease-pipeline-insight\" target=\"_blank\"><strong>Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment market<\/strong><\/a>. Several potential therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market size in the coming years.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Autosomal Dominant Polycystic Kidney Disease (ADPKD)&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autosomal-dominant-polycystic-kidney-disease-market\">Autosomal Dominant Polycystic Kidney Disease Market Insight, Epidemiology and Market Forecast -2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8221; Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2030&#8243; report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autosomal-dominant-polycystic-kidney-disease-epidemiology-forecast\">Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Autosomal Dominant Polycystic Kidney Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=autosomal-dominant-polycystic-kidney-disease-adpkd-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=autosomal-dominant-polycystic-kidney-disease-adpkd-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research &#8220;Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market. DelveInsight&#8217;s&nbsp;Autosomal Dominant Polycystic Kidney Disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/autosomal-dominant-polycystic-kidney-disease-adpkd-pipeline-assessment-key-companies-and-emerging-drugs_499440.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-499440","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499440"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499440\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}